Edmund K. Waller
Gründer bei Cambium Medical Technologies LLC
Profil
Edmund K.
Waller is the founder of Cambium Medical Technologies LLC, which was founded in 2013.
He held the title of Chief Scientific Officer & Director at the company.
He is currently working at Cambium Bio Ltd.
as the Executive Director & Chief Scientific Officer since 2024.
In his former positions, he served as the Chief Scientific Officer & Executive Director at Regeneus Ltd.
and as a Member-Advisory Board at Aldagen, Inc. Dr. Waller received his undergraduate degree from Cornell University and his doctorate degree from The Rockefeller University.
Aktive Positionen von Edmund K. Waller
| Unternehmen | Position | Beginn |
|---|---|---|
Cambium Medical Technologies LLC
 Cambium Medical Technologies LLC BiotechnologyHealth Technology Cambium Medical Technologies LLC develops and markets regenerative therapies derived from novel processed human platelets. The company was founded by Terence A. Walts, Jacques Galipeau, John D. Roback, Edmund K. Waller and Ian Copland in 2013 and is headquartered in Atlanta, GA. | Gründer | 01.08.2013 |
Ehemalige bekannte Positionen von Edmund K. Waller
| Unternehmen | Position | Ende |
|---|---|---|
| CAMBIUM BIO LIMITED | Technik-/Wissenschafts-/F&E-Leiter | - |
Aldagen, Inc.
 Aldagen, Inc. Pharmaceuticals: GenericHealth Technology Aldagen, Inc. develops and produces pharmaceutical products. It focuses on developing product candidates to address cardiovascular disease. The firm develops ALD-301 for the treatment of critical limb ischemia; ALD-201 for the treatment of ischemic heart failure; and ALD-401 for the post-acute treatment of ischemic stroke. The company also supplies ALDHbr cells for use in investigator-sponsored clinical studies. Aldagen was founded by Andrew E. Balber, Michael Sherman Colvin, Clay Smith and Nelson Chao in March 2000 and is headquartered in Durham, NC. | Corporate Officer/Principal | - |
Ausbildung von Edmund K. Waller
| Cornell University | Undergraduate Degree |
| The Rockefeller University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Aldagen, Inc.
Aldagen, Inc. Pharmaceuticals: GenericHealth Technology Aldagen, Inc. develops and produces pharmaceutical products. It focuses on developing product candidates to address cardiovascular disease. The firm develops ALD-301 for the treatment of critical limb ischemia; ALD-201 for the treatment of ischemic heart failure; and ALD-401 for the post-acute treatment of ischemic stroke. The company also supplies ALDHbr cells for use in investigator-sponsored clinical studies. Aldagen was founded by Andrew E. Balber, Michael Sherman Colvin, Clay Smith and Nelson Chao in March 2000 and is headquartered in Durham, NC. | Health Technology |
Regeneus Ltd.
 Regeneus Ltd. Pharmaceuticals: MajorHealth Technology Regeneus Ltd. is regenerative medicine company, which develops and commercializes innovative cell-based therapies to address unmet medical needs in human and veterinary health. The company was founded by Ben Herbert and Graham Vesey on August 14, 2007 and is headquartered in Paddington, Australia. | Health Technology |
Cambium Medical Technologies LLC
Cambium Medical Technologies LLC BiotechnologyHealth Technology Cambium Medical Technologies LLC develops and markets regenerative therapies derived from novel processed human platelets. The company was founded by Terence A. Walts, Jacques Galipeau, John D. Roback, Edmund K. Waller and Ian Copland in 2013 and is headquartered in Atlanta, GA. | Health Technology |
